从宏观解剖到微观分子成像看糖尿病胰腺的可视化技术进展

谭文彬; 李佳

doi:10.3969/j.issn.2095-5227.2023.04.001

从宏观解剖到微观分子成像看糖尿病胰腺的可视化技术进展

doi: 10.3969/j.issn.2095-5227.2023.04.001

谭文彬,
李佳^,

南部战区总医院内分泌科，广东广州　510010

基金项目: 国家自然科学基金项目(81701913)

详细信息

作者简介:
谭文彬，男，硕士。Email: tanwb0616@163.com

[专家简介]　李佳，医学博士，博士后，副主任医师，硕士研究生导师。现任南部战区总医院内分泌科主任。主要从事糖尿病急慢性并发症、各种类型甲状腺疾病、痛风、肥胖症、血脂紊乱等代谢病，垂体、肾上腺、罕见骨代谢疾病的综合管理及防治。作为项目负责人先后主持参与国家级、省部级课题6项；发表SCI、核心期刊论文40余篇；完成国内首个环境造模成功的高尿酸血症动物模型。筹建并成立广东省老年保健协会骨质疏松预防与康复专业委员会；兼任中国医药教育协会临床内分泌用药评价分会副主任委员、广东省老年保健协会骨质疏松预防与康复专委会主任委员、广州市医学会糖尿病分会副主任委员

通讯作者:
李佳，女，博士，副主任医师，主任。Email: gdnflj@126.com

中图分类号: R587.1
计量
- 文章访问数: 160
- HTML全文浏览量: 68
- PDF下载量: 26
- 被引次数: 0
出版历程
- 收稿日期: 2022-06-06
- 网络出版日期: 2023-03-02
- 刊出日期: 2023-04-28

Progress in visualization technology for diabetic pancreas from macroscopic anatomy to microscopic molecular imaging

TAN Wenbin,
LI Jia^,

Department of Endocrinology, General Hospital of Southern Theater Command, PLA, Guangzhou 510010, Guangdong Province, China

More Information

Corresponding author: LI Jia. Email: gdnflj@126.com

摘要

摘要: 胰腺作为分泌胰岛素的器官，随糖尿病(diabetes mellitus，DM)的发生、发展而产生相应病理改变，这其中可能蕴含着DM发病及进展的关键信息。除各种生化指标外，胰腺影像学也提供了反映DM胰腺的相关信息。超声、CT、磁共振及核医学成像技术，分别从胰腺外形、血流动力学信息、分子成像等方面实现非侵入性可视化DM患者胰腺。近年来，基于磁共振及核医学成像的β细胞成像技术取得了重大进展，尤其是利用核素标记胰高血糖素样肽-1受体靶向探针量化胰岛β细胞总数(β-cell mass，BCM)技术已初显成效，为胰岛BCM检测提供了先进的可视化方法。但受限于各类成像技术的应用条件且缺乏临床数据、判读标准和评估方法等，目前临床上仍无准确有效且安全性高的特异性评估DM胰腺成像方法。本文详细阐述了DM胰腺可视化技术的研究进展，以期为开发评估DM患者胰腺影像学工具提供参考。
- 糖尿病 /
- 胰腺 /
- 影像学 /
- 分子成像 /
- β细胞功能评估 /
- β细胞总数 /
- 胰高血糖素样肽-1受体靶向探针
Abstract: As the insulin-secreting organ, pancreas will appear a series of pathological changes with the occurrence and development of diabetes mellitus (DM), which may provide critical information about the onset and progression of DM. In addition to various kinds of biochemical indicators, pancreatic imaging techniques also provide relevant information reflecting pancreas of DM patients. Ultrasound, computed tomography, magnetic resonance imaging, and nuclear medicine imaging are applied to noninvasively visualize the pancreas of diabetic patients from the aspects of pancreatic appearance, hemodynamic information and molecular imaging. In recent years, the β-cell imaging technology, based mainly on magnetic resonance imaging and nuclear medical imaging techniques, has achieved significant progress. In particular, the technique of quantifying islet β-cell mass (BCM) by using radionuclide labeled glucagon-like peptide-1 receptor targeting probe has achieved remarkable results, offering novel visualization methods for islet BCM detection. However, due to the application conditions of various imaging techniques and the lack of relevant clinical data, effective and reliable interpretation standards and evaluation methods, there is still no accurate, effective and safe specific evaluation method for DM pancreas imaging in clinic. This paper elaborates the progress of pancreatic visualization technology in DM, so as to provide reference for the development of pancreatic imaging tools in patients with DM.
- diabetes mellitus /
- pancreas /
- imageology /
- molecular imaging /
- β-cell function assessment /
- β-cell mass /
- glucagon-like peptide-1 receptor targeting probe

HTML全文

参考文献(36)

[1]	Oh H,Park HJ,Oh J,et al. Hyperechoic pancreas on ultrasonography:an analysis of its severity and clinical implications[J]. Ultrasonography,2022,41(2): 335-343. doi: 10.14366/usg.21099
[2]	Oh J,Park HJ,Lee ES,et al. Severity of hyperechoic pancreas on ultrasonography as a risk factor for glycemic progression[J]. Ultrasonography,2021,40(4): 499-511. doi: 10.14366/usg.20122
[3]	He Y,Jin Y,Li XP,et al. Quantification of pancreatic elasticity in type 2 diabetes:a new potential imaging marker for evaluation of microangiopathy[J]. Eur J Radiol,2020,124: 108827. doi: 10.1016/j.ejrad.2020.108827
[4]	Salah NY,Madkour SS,Soliman KS. Pancreatic shear wave elastography in children with type 1 diabetes:relation to diabetes duration,glycemic indices,fasting C-peptide and diabetic complications[J]. Pediatr Radiol,2022,52(12): 2348-2358. doi: 10.1007/s00247-022-05363-1
[5]	St Clair JR,Ramirez D,Passman S,et al. Contrast-enhanced ultrasound measurement of pancreatic blood flow dynamics predicts type 1 diabetes progression in preclinical models[J]. Nat Commun,2018,9(1): 1742. doi: 10.1038/s41467-018-03953-y
[6]	Ramirez DG,Abenojar E,Hernandez C,et al. Contrast-enhanced ultrasound with sub-micron sized contrast agents detects insulitis in mouse models of type1 diabetes[J]. Nat Commun,2020,11(1): 2238. doi: 10.1038/s41467-020-15957-8
[7]	苏丽平,陈杭,唐苏丹,等. 基于CT图像影像组学模型在糖尿病患者胰腺功能分析中的应用[J]. 中国医学影像学杂志,2022,30(1): 60-65. doi: 10.3969/j.issn.1005-5185.2022.01.013
[8]	Jang S,Kim JH,Choi SY,et al. Application of computerized 3D-CT texture analysis of pancreas for the assessment of patients with diabetes[J]. PLoS One,2020,15(1): e0227492. doi: 10.1371/journal.pone.0227492
[9]	邹斌. 2型糖尿病患者胰腺多排螺旋CT灌注结果分析[J]. 糖尿病新世界,2020,23(18): 34-35. doi: 10.16658/j.cnki.1672-4062.2020.18.034
[10]	Şahan MH,Özdemir A,Asal N,et al. Pancreas and kidney changes in type 2 diabetes patients:the role of diffusion-weighted imaging[J]. Turk J Med Sci,2021,51(3): 1289-1295. doi: 10.3906/sag-2011-176
[11]	Tokunaga A,Imagawa A,Nishio H,et al. Diffusion-weighted magnetic resonance imaging in the pancreas of fulminant type 1 diabetes[J]. Diabetol Int,2018,9(4): 257-265. doi: 10.1007/s13340-018-0355-1
[12]	Canzano JS,Nasif LH,Butterworth EA,et al. Islet microvasculature alterations with loss of beta-cells in patients with type 1 diabetes[J]. J Histochem Cytochem,2019,67(1): 41-52. doi: 10.1369/0022155418778546
[13]	Chen J,Chen JQ,Cheng YH,et al. Mesenchymal stem cell-derived exosomes protect beta cells against hypoxia-induced apoptosis via miR-21 by alleviating ER stress and inhibiting p38 MAPK phosphorylation[J]. Stem Cell Res Ther,2020,11(1): 97. doi: 10.1186/s13287-020-01610-0
[14]	Feng YZ,Ye YJ,Cheng ZY,et al. Non-invasive assessment of early stage diabetic nephropathy by DTI and BOLD MRI[J]. Br J Radiol,2020,93(1105): 20190562. doi: 10.1259/bjr.20190562
[15]	陈伯柱. 糖尿病相关胰腺改变的磁共振定量评估［D］. 南京: 南京医科大学, 2018.
[16]	Taso M,Papadopoulou F,Smith MP,et al. Pancreatic perfusion modulation following glucose stimulation assessed by noninvasive arterial spin labeling (ASL) MRI[J]. J Magn Reson Imaging,2020,51(3): 854-860. doi: 10.1002/jmri.26899
[17]	Cline GW,McCarthy TJ,Carson RE,et al. Clinical and scientific value in the pursuit of quantification of beta cells in the pancreas by PET imaging[J]. Diabetologia,2018,61(12): 2671-2673. doi: 10.1007/s00125-018-4718-8
[18]	Balhuizen A,Massa S,Mathijs I,et al. A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells[J]. Sci Rep,2017,7(1): 15130. doi: 10.1038/s41598-017-15417-2
[19]	Demine S,Garcia Ribeiro R,Thevenet J,et al. A nanobody-based nuclear imaging tracer targeting dipeptidyl peptidase 6 to determine the mass of human beta cell grafts in mice[J]. Diabetologia,2020,63(4): 825-836. doi: 10.1007/s00125-019-05068-5
[20]	Tornehave D,Kristensen P,Rømer J,et al. Expression of the GLP-1 receptor in mouse,rat,and human pancreas[J]. J Histochem Cytochem,2008,56(9): 841-851. doi: 10.1369/jhc.2008.951319
[21]	Cheung P,Eriksson O. The current state of beta-cell-mass PET imaging for diabetes research and therapies[J]. Biomedicines,2021,9(12): 1824. doi: 10.3390/biomedicines9121824
[22]	Li LL,Zhao RY,Hong HY,et al. 68Ga-labelled-exendin-4:new GLP1R targeting agents for imaging pancreatic β-cell and insulinoma[J]. Nucl Med Biol,2021,102/103: 87-96. doi: 10.1016/j.nucmedbio.2021.10.001
[23]	Boss M,Buitinga M,Jansen TJP,et al. PET-based human dosimetry of 68Ga-NODAGA-exendin-4,a tracer for β-cell imaging[J]. J Nucl Med,2020,61(1): 112-116. doi: 10.2967/jnumed.119.228627
[24]	Joosten L,Brom M,Peeters H,et al. Measuring the pancreatic β cell mass in vivo with exendin SPECT during hyperglycemia and severe insulitis[J]. Mol Pharm,2019,16(9): 4024-4030. doi: 10.1021/acs.molpharmaceut.9b00728
[25]	Eriksson O,Rosenström U,Selvaraju RK,et al. Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4[J]. Acta Diabetol,2017,54(11): 1039-1045. doi: 10.1007/s00592-017-1046-2
[26]	Eriksson O,Johnström P,Cselenyi Z,et al. In vivo visualization of β-cells by targeting of GPR44[J]. Diabetes,2018,67(2): 182-192. doi: 10.2337/db17-0764
[27]	Cheung P,Zhang B,Puuvuori E,et al. PET imaging of GPR44 by antagonist[11C]MK-7246 in pigs[J]. Biomedicines,2021,9(4): 434. doi: 10.3390/biomedicines9040434
[28]	Eriksson O. GPR44 as a target for imaging pancreatic beta-cell mass[J]. Curr Diab Rep,2019,19(8): 49. doi: 10.1007/s11892-019-1164-z
[29]	Farino ZJ,Morgenstern TJ,Maffei A,et al. New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion[J]. Mol Psychiatry,2020,25(9): 2070-2085. doi: 10.1038/s41380-018-0344-6
[30]	Bini J,Sanchez-Rangel E,Gallezot JD,et al. PET imaging of pancreatic dopamine D2 and D3 receptor density with 11C-( + )-PHNO in type 1 diabetes[J]. J Nucl Med,2020,61(4): 570-576. doi: 10.2967/jnumed.119.234013
[31]	Wei WJ,Ehlerding EB,Lan XL,et al. Molecular imaging of β-cells:diabetes and beyond[J]. Adv Drug Deliv Rev,2019,139: 16-31. doi: 10.1016/j.addr.2018.06.022
[32]	肖见飞,姜东朗,任树华,等. 2型囊泡单胺转运体分子探针18F-FP-( + )-DTBZ定量1型糖尿病大鼠胰岛β细胞总量纵向研究[J]. 中华内分泌代谢杂志,2019,35(6): 494-498. doi: 10.3760/cma.j.issn.1000-6699.2019.06.009
[33]	Cline GW,Naganawa M,Chen LG,et al. Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging[J]. Diabetologia,2018,61(12): 2598-2607. doi: 10.1007/s00125-018-4624-0
[34]	Zhao TJ,Huang QF,Su YN,et al. Zinc and its regulators in pancreas[J]. Inflammopharmacology,2019,27(3): 453-464. doi: 10.1007/s10787-019-00573-w
[35]	Thapa B,Suh EH,Parrott D,et al. Imaging β-cell function using a zinc-responsive MRI contrast agent may identify first responder islets[J]. Front Endocrinol (Lausanne),2021,12: 809867.
[36]	Clavijo Jordan V,Hines CDG,Gantert LT,et al. Imaging beta-cell function in the pancreas of non-human Primates using a zinc-sensitive MRI contrast agent[J]. Front Endocrinol (Lausanne),2021,12: 641722. doi: 10.3389/fendo.2021.641722